Reduction of Ischemia-Reperfusion Mediated Cardiac Injury in Subjects Undergoing Coronary Artery Bypass Graft Surgery
Phase 2
Terminated
- Conditions
- Coronary Artery Bypass Surgery
- Interventions
- Drug: Normal Saline
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 6
- Registration Number
- NCT00858936
- Locations
- 🇦🇺
Flinder Medical Center, Bedford Park, South Australia, Australia
🇦🇺Alfred Hospital, Melbourne, Victoria, Australia
🇨🇦Royal Victoria Hospital - MUHC, Montreal, Quebec, Canada
Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg Tablets
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Roxicodone™ tablet 15 mg
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 38
- Registration Number
- NCT00853320
- Locations
- 🇺🇸
Gateway Medical Research, St. Charles, Missouri, United States
Fasting Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Controlled-Release Oxycodone Hydrochloride 40 mg tablet
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 34
- Registration Number
- NCT00853892
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, Springfield, Missouri, United States
Fasting Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Roxicodone™ tablet 30 mg
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 38
- Registration Number
- NCT00853216
- Locations
- 🇺🇸
Gateway Medical Research, St. Charles, Missouri, United States
Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Roxicodone™ tablet 30 mg
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 23
- Registration Number
- NCT00853736
- Locations
- 🇺🇸
Gateway Medical Research, St. Charles, Missouri, United States
Fasting Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 42
- Registration Number
- NCT00853294
Fasting Study of Hydromorphone Hydrochloride 8 mg Tablets and Dilaudid 8 mg Tablets
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 24
- Registration Number
- NCT00853554
- Locations
- 🇺🇸
Gateway Medical Research, St. Charles, Missouri, United States
Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 43
- Registration Number
- NCT00853190
- Locations
- 🇺🇸
Gateway Medical Research, St. Charles, Missouri, United States
Fed Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Controlled-Release Oxycodone Hydrochloride 40 mg
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 34
- Registration Number
- NCT00853268
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, Springfield, Missouri, United States
The Effects of Nitric Oxide for Inhalation in Right Ventricular Infarction Patients
Phase 2
Terminated
- Conditions
- Right Ventricular Infarction
- Interventions
- Drug: inhaled nitric oxide
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 3
- Registration Number
- NCT00782652
- Locations
- 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇵🇱Institute of Cardiology Warsaw, Alpejska, Poland
© Copyright 2025. All Rights Reserved by MedPath